Patients had a diagnosis of nonmyeloid malignancy with ≥ 8 weeks of planned chemotherapy, age ≥ 18 years, and anemia (hemoglobin ≤ 11 g/dL). Patients were randomly assigned 1:1 to DA 200 μg every two ...

We also think this car is quite a looker, especially for an SUV. The trademark Alfa Romeo shield grille is present and powerful on the front end, sculpted side panels look fast even while parked ...

A rear-drive base variant is now available on the 2019 Alfa Romeo Stelvio, which now makes Apple CarPlay and Android Auto standard on all trims. Heated rear seats are now optional on all grades ...

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

bDepartment of Pediatrics, University of Washington, Seattle, WA, USA cDepartment of Biostatistics, University of Washington, Seattle, WA, USA dTranslational Medicine Research Institute, The Hospital ...

Darbepoetin was well tolerated and conveniently coordinated with cyclic chemotherapy. Ten patients maintained a hemoglobin concentration of ≥11 g/dL for at least two treatment periods.

According to the rumor mill and also via official sources, the second-generation Alfa Romeo Stelvio will get its five minutes of official red-carpet glory during the second half of the year.

An Alfa Romeo official hinted at the possibility of a premium sports car coming soon. The model could arrive sometime after the brand launches the new Giulia and Stelvio. Speculation suggests it ...

He discusses the role of darbepoetin alfa (Cresp) in improving and maintaining hemoglobin levels, enhancing patient tolerance to therapy, and ensuring continuity of cancer treatment. The case involves ...

Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS-CoV-2 infection-even when standard medical tests return normal ...

“Invikafusp alfa is a novel bi-specific immunotherapy designed as a dual T cell agonist, and the recent AACR presentation highlighting its single-agent activity in PD-1 resistant tumors is ...